DENTSPLY SIRONA (XRAY) Q4 2020 earnings summary

Executive summary

• FY20 sales fell 17.1% as COVID-19 restrictions reduced dental procedures; demand reached its low in April and improved through H2.

• Net loss was $83M versus $263M net income in FY19, while operating cash flow remained strong at $635M.

• Strategic actions included restructuring, exiting low-growth product lines, and acquiring Byte to expand clear aligner scale and digital reach.

Financial highlights

• Revenue was $3.342B, down 17.1% reported and 16.7% organically YoY; weaker U.S. dollar added 0.3%.

• Gross profit was $1.657B, down 23.5%; gross margin was 49.6%, down 410 bps YoY amid lower volume, manufacturing variances, accelerated depreciation and inventory write-downs.

• Operating loss was $12M versus $361M operating income in FY19; diluted EPS was $(0.38) versus $1.17.

• SG&A was $1.435B, down 16.7%, but increased to 42.9% of sales from 42.8%; goodwill impairment was $157M and restructuring and other costs were $77M in the income statement.

• Operating cash flow was $635M, up $2M YoY; cash and equivalents ended at $438M, up $33M.

Outlook and guidance

• Restructuring targets: 3%–4% annualized sales growth, 22% adjusted operating margin by end-2022, and $250M annual savings under the expanded plan.

• FY21 capital expenditures expected at $135M–$160M; restructuring cash payments expected at $50M–$100M.

• COVID-19 restrictions, procedure levels and patient willingness to seek care leave the pace of recovery uncertain; management expected possible negative operating impact in 2021.

• Integration of Byte and Datum, increased R&D, digital capabilities and operating efficiency were priorities for 2021.